Eli Lilly is creating a formal path for a small number of patients to receive retatrutide before the experimental obesity drug is approved by the U.S. Food and Drug Administration.
The Eli Lilly retatrutide early access program is intended for adults with severe obesity who have serious related health problems, have not responded adequately to approved treatments and cannot join an active clinical trial.
It is not a public launch of retatrutide and patients cannot request the drug directly from a pharmacy. A treating physician must apply on the patient’s behalf, and each case requires review by Lilly, the FDA and an institutional review board.
Who Could Qualify for Eli Lilly Retatrutide Early Access?
Lilly said applicants must be at least 18 and have refractory obesity, meaning the condition has remained severe despite treatment with the highest tolerated dose of an approved obesity medication.
Patients must also have at least two serious or life-threatening medical conditions connected to obesity. Those conditions could include severe sleep apnea, pulmonary hypertension, cardiovascular disease or other complications that place the patient at substantial risk.
Another requirement is that the person cannot take part in a suitable clinical trial involving retatrutide or another experimental treatment.
Eli Lilly confirmed the early-access plan after doctors began asking why one unidentified patient had already received the drug outside a clinical trial.
Meeting the stated conditions does not guarantee treatment. Lilly will review each request and consider the patient’s medical need, the available safety information and whether providing the drug could interfere with ongoing research.
One Patient’s Case Prompted Wider Demands for Access
View this post on Instagram
The issue drew attention after a 79-year-old patient reportedly received retatrutide through the FDA’s expanded access process, also known as compassionate use.
The patient had severe obesity and serious related conditions after previous treatment with tirzepatide, the active ingredient in Zepbound and Mounjaro.
The patient’s identity has not been disclosed. Doctors treating other patients with similar medical problems then asked Lilly to explain how they could pursue the same option.
Physicians seeking access for additional patients were told that the company had established a formal review process.
The move gives doctors a clearer route than the earlier single-patient arrangement. Lilly has not said how many patients will be accepted or how long each review will take.
Retatrutide Has Produced Unusually Large Weight Loss in Trials
Retatrutide is a weekly injection that targets three hormone pathways involved in appetite, blood sugar and metabolism: GLP-1, GIP and glucagon.
That distinguishes it from semaglutide, which targets GLP-1, and tirzepatide, which targets GLP-1 and GIP.
Interest in early access is being driven by strong late-stage trial results. NCHStats previously reported that Eli Lilly’s experimental weight-loss drug produced results approaching those seen after bariatric surgery.
In a Phase 3 study, participants receiving the highest dose lost an average of about 28% of their body weight. Results from longer treatment periods have placed average weight loss near 30% for some groups.
Those figures are averages from controlled trials. They do not mean every patient will lose the same amount or that the drug has already been proven safe for widespread use.
Our comparison of bariatric surgery and current weight-loss medications explains why trial results and outcomes in everyday medical care can differ substantially.
What is Expanded Access?
Expanded access is a federal process that permits a patient with a serious or life-threatening condition to receive an unapproved medicine outside a clinical trial.
Under FDA expanded access rules, there must be no comparable approved treatment available, the potential benefit must justify the risk and access must not disrupt the studies required for approval.
The physician first contacts the manufacturer. When the company agrees to supply the medicine, the doctor submits a treatment plan to the FDA and obtains review from an institutional review board.
The patient must also give informed consent after receiving an explanation of the known and unknown risks.
Expanded access is therefore different from an ordinary prescription. Retatrutide remains experimental, and regulators have not completed their review of its safety, effectiveness or manufacturing process.
Retatrutide Is Not Available for Routine Weight Loss
The announcement does not make retatrutide available to people seeking a stronger alternative to Ozempic, Wegovy, Mounjaro or Zepbound.
Authentic retatrutide is currently supplied only through authorized clinical trials or approved expanded access cases.
Products advertised online as retatrutide are not FDA-approved versions of Lilly’s medicine. The agency has warned sellers against marketing unapproved retatrutide and other experimental peptides.
People using current GLP-1 drugs also face practical issues involving nutrition, muscle loss and long-term adherence. Our report on weight-loss injections and nutritional risks explains why medical supervision remains important even for approved treatments.
What Patients and Doctors Should Do?
A patient who believes they qualify should speak with the obesity specialist or physician managing the related medical conditions.
The doctor should first review approved medications and search for an available clinical trial. The federal clinical trial database lists current studies, eligibility rules and participating locations.
When no trial or approved treatment is suitable, the physician can contact Lilly about an individual expanded access request.
Patients should not buy products labeled retatrutide from online sellers or attempt to obtain the experimental drug without medical supervision.
Approval Is Still Expected Later
Lilly is continuing its Phase 3 research and is expected to seek U.S. approval after the required studies are completed.
The company’s published trial update describes retatrutide as a triple-hormone receptor agonist and reports substantial weight reduction in late-stage testing.
The Eli Lilly retatrutide early access program gives a narrow group of seriously ill patients a possible route to treatment before that review is finished. It does not make retatrutide available to the wider public, and it does not replace the FDA approval process.
